Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
Status:
Enrolling by invitation
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or
nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary
tract cancers.